GANX
Gain TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
GT-02287 has generated biomarker and target-engagement signals, management is guiding to IND clearance in 2Q26 and Phase 2 start in 3Q26, and successful execution could re-rate shares from a depressed base [#8-K-2026-03-26].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Going-concern disclosure and likely need for additional capital.
Momentum
82
Value
41
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.80 · Bull $3.40 · Bear $0.80
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $7.20
Why
Momentum82 · Δ7d -
Value41 · Δ7d +0.0
Sentiment60 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
82
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
60
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 82.4 / Value 41.1 / Sentiment 60.5
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$69.53M
Beta
0.07
Shares Out
42.65M
P/E (TTM) · Derived
-2.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.04
Rev YoY
-100.0%
EPS YoY
-15.9%
Gross Margin
-51.5%
Op Margin
-
Net Debt
-$20.11M
Current Ratio
4.69
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology